|
|
Post by mnholdem on May 17, 2018 8:49:33 GMT -5
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS 27th ANNUAL SCIENTIFIC & CLINICAL CONGRESS Boston, MA • May 16-20, 2018
Booth 1524 - Sanofi / Sanofi Regeneron Booth 1417 - MannKind Corporation Booth Booth 1409 - Novo Nordisk - Diabetes Care
www.eventscribe.com/2018/AACE/exhibitors/
This location should be getting some good foot traffic this week, IMO:
|
|
|
|
Post by mnholdem on May 17, 2018 8:58:47 GMT -5
One of the 2018 AACE Abstracts deals with a favorite subject of mine, one which I've long advocated for Afrezza:
Abstract #255
EARLY INTENSIFIED INSULIN THERAPY IN
NEWLY DIAGNOSED TYPE 2 DIABETES LEADS
TO SUSTAINED IMPROVEMENT IN GLYCEMIC
CONTROL AND IMPROVED BETA CELL FUNCTION
Jatinder Mokta, MD, FACP, FRCP1, Viswanathan Mohan,
MD, FRCP, FACE, MACP2
1. IGMC Shimla, 2. dr. Mohan’s Diabetes Specialities Centre
Objective: Type 2 diabetes (T2D) is a progressive disease
characterized by relentless deterioration of pancreatic
β-cell function. Traditionally, insulin is used in later stages
of T2DM. This study looks at use of insulin at time of
diagnosis of T2D and its effect on glycemic control and
beta cell function.
Methods: This is a prospective observational study
conducted in symptomatic newly diagnosed type 2
diabetes adults (>18 years) who presented with glycated
hemoglobin (A1C) levels > 9%. For the initial 8 weeks,
patients were treated with pre-mix insulin after which they
were changed over to oral agents, and followed up for next
three years.
Results: Of 122 study participants, who completed the
study, 50% were female and 90% were from rural areas.
Average age of participants was 51.4 ± 9.6 years. Baseline
mean fasting plasma glucose (FPG), post prandial plasma
glucose (PPPG) and A1C were 267 ± 76 mg/dl, 408 ± 101
mg/dl and 11.5 ± 1.4% respectively. At the end of insulin
therapy (8 weeks), the mean FPG, PPG and A1C reduced to
107 ± 10 mg/dl, 145 ± 24 mg/dl and 7.3 ± 0.8% respectively
all of which were highly significant. The mean post-prandial
C-peptide significantly increased from 1.8± 0.6 to 2.8± 0.9
ng/dl. An average of 1.7 kg weight gain and 0.97 episodes
of mild to moderate hypoglycemia were observed. At the
end of study (156 weeks), the mean FPG, PPG and A1C
were 99 ± 14 mg/dl, 152 ± 12 mg/dl and 6.7 ± 0.4%.
Conclusion: helps to maintain long term normoglycemia
and improves β-cell function. Early insulin therapy in
treatment naïve patients with type 2 diabetes results in
rapid improvement of glycemic control.
Source: am.aace.com/files/Abstract-Book-2018.pdf
|
|
|
|
Post by uvula on May 17, 2018 8:59:59 GMT -5
Great location. The booth is surprisingly large too.
|
|
|
|
Post by kc on May 17, 2018 9:05:09 GMT -5
Great location. The booth is surprisingly large too. Boutique trade show to a very specialized group. Cost a booth is much less then a big show like ADA. |
|
|
|
Post by esstan2001 on May 17, 2018 9:23:53 GMT -5
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS 27th ANNUAL SCIENTIFIC & CLINICAL CONGRESS Boston, MA • May 16-20, 2018
Booth 1524 - Sanofi / Sanofi Regeneron Booth 1417 - MannKind Corporation Booth Booth 1409 - Novo Nordisk - Diabetes Care
www.eventscribe.com/upload/planner/floorplans/2018AACE-Mixed_50.png
This location should be getting some good foot traffic this week, IMO:
wow smack in the middle- not bad. |
|
|
|
Post by mnholdem on May 17, 2018 9:29:23 GMT -5
My apologies. I provided an incorrect link in the OP (I corrected above). Here is the link to the 2018 AACE floorplan:
www.eventscribe.com/2018/AACE/exhibitors/
MannKind is in the group on the right side of the convention floor. |
|
|
|
Post by #NoMoreNeedles on May 17, 2018 9:52:37 GMT -5
The war is on!
|
|
|
|
Post by peppy on May 17, 2018 10:01:06 GMT -5
My apologies. I provided an incorrect link in the OP (I corrected above). Here is the link to the 2018 AACE floorplan:
www.eventscribe.com/2018/AACE/exhibitors/
MannKind is in the group on the right side of the convention floor. strategically located close to the food service area. always thinking. |
|
|
|
Post by bioexec25 on May 17, 2018 13:40:21 GMT -5
Maybe Mnkd will be singing Stealers Wheels.
Well I don't know why I came here tonight,
I got the feeling that something ain't right,
I'm so scared in case I fall off my chair,
And I'm wondering how I'll get down the stairs,
Clowns to the left of me,
Jokers to the right, here I am,
Stuck in the middle with you
|
|
|
|
Post by dreamboatcruise on May 17, 2018 16:22:18 GMT -5
One of the 2018 AACE Abstracts deals with a favorite subject of mine, one which I've long advocated for Afrezza:
Abstract #255
EARLY INTENSIFIED INSULIN THERAPY IN
NEWLY DIAGNOSED TYPE 2 DIABETES LEADS
TO SUSTAINED IMPROVEMENT IN GLYCEMIC
CONTROL AND IMPROVED BETA CELL FUNCTION
Jatinder Mokta, MD, FACP, FRCP1, Viswanathan Mohan,
MD, FRCP, FACE, MACP2
1. IGMC Shimla, 2. dr. Mohan’s Diabetes Specialities Centre
Objective: Type 2 diabetes (T2D) is a progressive disease
characterized by relentless deterioration of pancreatic
β-cell function. Traditionally, insulin is used in later stages
of T2DM. This study looks at use of insulin at time of
diagnosis of T2D and its effect on glycemic control and
beta cell function.
Methods: This is a prospective observational study
conducted in symptomatic newly diagnosed type 2
diabetes adults (>18 years) who presented with glycated
hemoglobin (A1C) levels > 9%. For the initial 8 weeks,
patients were treated with pre-mix insulin after which they
were changed over to oral agents, and followed up for next
three years.
Results: Of 122 study participants, who completed the
study, 50% were female and 90% were from rural areas.
Average age of participants was 51.4 ± 9.6 years. Baseline
mean fasting plasma glucose (FPG), post prandial plasma
glucose (PPPG) and A1C were 267 ± 76 mg/dl, 408 ± 101
mg/dl and 11.5 ± 1.4% respectively. At the end of insulin
therapy (8 weeks), the mean FPG, PPG and A1C reduced to
107 ± 10 mg/dl, 145 ± 24 mg/dl and 7.3 ± 0.8% respectively
all of which were highly significant. The mean post-prandial
C-peptide significantly increased from 1.8± 0.6 to 2.8± 0.9
ng/dl. An average of 1.7 kg weight gain and 0.97 episodes
of mild to moderate hypoglycemia were observed. At the
end of study (156 weeks), the mean FPG, PPG and A1C
were 99 ± 14 mg/dl, 152 ± 12 mg/dl and 6.7 ± 0.4%.
Conclusion: helps to maintain long term normoglycemia
and improves β-cell function. Early insulin therapy in
treatment naïve patients with type 2 diabetes results in
rapid improvement of glycemic control.
Source: am.aace.com/files/Abstract-Book-2018.pdf
Interesting they call that "early"... I perhaps would have called in "marginally earlier"  Surprised by low incidence of hypos. Overall, I'm disappointed in the study design. It seems these patients had no prior treatment, so the results would be much more meaningful if it had an arm where half the patients were immediately put on oral agents without the short term insulin. From what's presented it doesn't seem like you can say adding the short term insulin had any benefit over just orals. |
|
|
|
Post by dh4mizzou on May 17, 2018 16:43:13 GMT -5
DBC,
Don't know if you have kids but, if you did, you must have been a hoot with them.
Yes Suzie that picture is nice BUT.....
Yes little Johny I know you hit a home run BUT.....
And I bet you're the life of the party presumming you get invited to any.
|
|
|
|
Post by mnholdem on May 17, 2018 16:47:08 GMT -5
Perhaps that's because there have been numerous trials to that effect. I cannot speak to other OADs, but Metformin does nothing to compare itself to the Conclusion in this and other studies, particularly with regard to β-cell function. The key words in this Conclusion, for me anyway, is early insulin helps "long term".
|
|
|
|
Post by mnholdem on May 17, 2018 16:49:54 GMT -5
I notice that there is a short cut or Pass-Through (fortunately) straight to the food court for physicians in attendance who are like liane .
It appears that MannKind thought of everything.  |
|
|
|
Post by dreamboatcruise on May 17, 2018 16:52:09 GMT -5
Perhaps that's because there have been numerous trials to that effect. I cannot speak to other OADs, but Metformin does nothing to compare itself to the Conclusion in this and other studies, particularly with regard to β-cell function. The key words in this Conclusion, for me anyway, is early insulin helps "long term". Maybe it's just a poorly written abstract. I don't see how they would have drawn that conclusion based on the methodology and the "results" they list... but perhaps, as I think you're saying, they are comparing the long term results they obtained with prior studies using the same OADs. Just think it would have more impact if that had comparison arm especially if blinded. |
|
|
|
Post by sportsrancho on May 17, 2018 16:52:24 GMT -5
Maybe Mnkd will be singing Stealers Wheels. Well I don't know why I came here tonight, I got the feeling that something ain't right, I'm so scared in case I fall off my chair, And I'm wondering how I'll get down the stairs, Clowns to the left of me,
Jokers to the right, here I am, Stuck in the middle with you Hilarious! |
|
